Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma

NCT03275103 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03275103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03275103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2017
Completion date
January 7, 2026
Enrollment
355 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma